4R tauopathies, including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Primary Age-Related Tauopathy (PART), represent a significant unmet need in neurodegenerative disease investment. Unlike 3R+4R tauopathies (Alzheimer's disease), these disorders feature tau pathology composed exclusively of 4-repeat tau isoforms, creating distinct therapeutic targeting opportunities. This analysis examines the current investment landscape, pipeline dynamics, and research gaps for 4R tauopathy-directed therapeutics. [1]
Mechanism: Small molecules preventing tau oligomerization and fibril formation [2]
Pipeline Status: [3]
Investment Opportunity: Moderate - early-stage but validated mechanism [4]
Targets: GSK-3β, CDK5, DYRK1A, PP2A [5]
Pipeline: [6]
Investment Opportunity: High - multiple validated targets in development [7]
Approaches: Active vaccines, passive antibodies, antibody fragments [8]
Pipeline: [9]
Investment Opportunity: High - significant pharmaceutical investment
Mechanism: Preserve tau-depleted neuronal transport
Pipeline:
Investment Opportunity: Moderate - validated mechanism but clinical results mixed
Rationale: 4R tauopathies specifically involve 4-repeat isoform dysfunction
Emerging Strategies:
Investment Opportunity: High - uniquely targeted approach
| Company | Focus Area | Development Stage |
|---|---|---|
| Biogen | Tau antibodies | Phase III |
| Roche | Tau antibodies | Phase III |
| Eli Lilly | Tau immunotherapeutics | Phase II/III |
| TauRx (Wisemodel) | Aggregation inhibitors | Phase III |
| AbbVie | GSK-3β inhibitors | Phase I |
| Bristol Myers Squibb | CDK5 inhibitors | Preclinical |
| Trial | Intervention | Phase | Status | NCT |
|---|---|---|---|---|
| NCT04576364 | Tilavonemab (ABBV-8E12) | II | Recruiting | NCT04576364 |
| NCT04040017 | Gosuranemab (BIIB080) | II | Active | NCT04040017 |
| NCT03474107 | Tideglusib | II | Completed | NCT03474107 |
The 4R tauopathy investment landscape presents substantial opportunities for therapeutic development, with significant unmet need in PSP and CBD. While challenges exist in clinical trial design and biomarker validation, the increasing pharmaceutical investment and scientific understanding create a favorable environment for strategic investment. The unique 4R-tau specificity represents a differentiated opportunity compared to broader tauopathy approaches.
Boxer AL, et al. Clinical features of progressive supranuclear palsy. Lancet Neurol. 2019. ↩︎
Armstrong MJ, et al. Corticobasal syndrome. Lancet Neurol. 2016. ↩︎
Crary JF, et al. Primary age-related tauopathy (PART). Acta Neuropathol. 2014. ↩︎
Wischik CM, et al. Tau aggregation inhibitor therapy in Alzheimer's disease. Alzheimers Dement. 2018. ↩︎
Pagan F, et al. Nilotinib effects in Parkinson's disease. J Parkinsons Dis. 2019. ↩︎
Tolosa E, et al. Tideglusib in progressive supranuclear palsy. Lancet Neurol. 2014. ↩︎
Novak P, et al. Tau vaccine AADvac1. Lancet Neurol. 2017. ↩︎
Boxer AL, et al. Davunetide in PSP. Lancet Neurol. 2015. ↩︎